We are live on ! Find out more
CLCD

CoLucid Pharmaceuticals, Inc.
CLCD

Delisted

CLCD was delisted on the 28th of February, 2017.

Back to rankings

76 hedge funds and large institutions have $503M invested in CoLucid Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 9

36% more funds holding

Funds holding: 56 → 76 (+20)

7% more capital invested

Capital invested by funds: $472M → $503M (+$30.7M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

Holders
76
Holders Change
+20
Holders Change %
+35.71%
% of All Funds
1.9%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
30
Increased
18
Reduced
18
Closed
9
Calls
$859K
Puts
–
Net Calls
+$859K
Net Calls Change
+$859K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$22.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.9M
3
Marshall Wace
Marshall Wace
United Kingdom
+$10.8M
4
BFA
BlackRock Fund Advisors
California
+$9.47M
5
CS
Credit Suisse
Switzerland
+$5.39M

Top Sellers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
-$10.9M
2
BI
BVF Inc
California
-$9.87M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.51M
4
CIP
Chartwell Investment Partners
Pennsylvania
-$5.08M
5
NC
Nexthera Capital
New York
-$3.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
SIM
26
Spark Investment Management
New York
$2.64M +$2.57M +72,600 New
ACM
27
Atika Capital Management
New York
$2.49M -$234K -6,600 -9%
VM
28
VHCP Management
New York
$2.48M – – –
KCM
29
Kingdon Capital Management
New York
$2.2M -$3.34M -94,502 -61%
BCM
30
Bridgeway Capital Management
Texas
$2.18M -$354K -10,000 -14%
TD Asset Management
31
TD Asset Management
Ontario, Canada
$2.04M -$14.2K -400 -0.7%
Geode Capital Management
32
Geode Capital Management
Massachusetts
$1.96M +$180K +5,082 +10%
WMSA
33
Weiss Multi-Strategy Advisers
New York
$1.82M +$637K +18,000 +56%
Russell Investments Group
34
Russell Investments Group
United Kingdom
$1.58M +$1.52M +42,998 New
Renaissance Technologies
35
Renaissance Technologies
New York
$1.51M -$1.8M -51,000 -55%
BBA
36
Baker Bros. Advisors
New York
$1.1M – – –
Allianz Asset Management
37
Allianz Asset Management
Germany
$1.09M +$1.06M +29,989 New
Ameriprise
38
Ameriprise
Minnesota
$1.08M -$962K -27,197 -48%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.02M -$345K -9,756 -26%
Northern Trust
40
Northern Trust
Illinois
$652K +$243K +6,864 +62%
Goldman Sachs
41
Goldman Sachs
New York
$597K +$580K +16,404 New
SSA
42
Schonfeld Strategic Advisors
New York
$591K +$575K +16,240 New
PPA
43
Parametric Portfolio Associates
Washington
$531K -$815K -23,025 -61%
Morgan Stanley
44
Morgan Stanley
New York
$499K +$34.9K +986 +8%
ProShare Advisors
45
ProShare Advisors
Maryland
$463K +$450K +12,716 New
Swiss National Bank
46
Swiss National Bank
Switzerland
$444K +$432K +12,200 New
Neuberger Berman Group
47
Neuberger Berman Group
New York
$437K – – –
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$435K +$422K +11,939 New
State Street
49
State Street
Massachusetts
$422K +$410K +11,600 New
Deutsche Bank
50
Deutsche Bank
Germany
$395K +$385K +10,869 New
1
2
3 4

CLCD Hedge Fund Activity: Q4 2016 in Review

76 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q4 2016, worth a combined $503M — up 6.5% from $472M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new CLCD positions and 9 closed out — a net gain of 21 holders — while 18 added to existing stakes and 18 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $22.2M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $10.9M sold.

  • 76 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q4 2016, up from 56 in Q3 2016.
  • Funds reported $503M of CoLucid Pharmaceuticals, Inc. stock for Q4 2016, up 6.5% quarter-over-quarter.
  • 30 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q4 2016 and 9 closed out, a net change of +21 holders.
  • The largest CoLucid Pharmaceuticals, Inc. buyer in Q4 2016 was Citadel Advisors, an estimated $22.2M added.
  • The largest CoLucid Pharmaceuticals, Inc. seller in Q4 2016 was EverPoint Asset Management, an estimated $10.9M sold.

Based on aggregated 13F filings for Q4 2016.